Epilepsy drug safety trial in kids ends early
NCT ID NCT05301894
First seen Feb 23, 2026 · Last updated May 23, 2026 · Updated 13 times
Summary
This study looked at the long-term safety of the drug NBI-827104 in children with a rare form of epilepsy that causes continuous brain-wave spikes during sleep. The trial was stopped early, but it aimed to track serious side effects in 19 children. The goal was to see if the drug is safe enough to control seizures over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPTIC ENCEPHALOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Neurocrine Clinical Site
Orange, California, 92868, United States
-
Neurocrine Clinical Site
Aurora, Colorado, 80045, United States
-
Neurocrine Clinical Site
Washington D.C., District of Columbia, 20010, United States
-
Neurocrine Clinical Site
Miami, Florida, 33155, United States
-
Neurocrine Clinical Site
Rochester, Minnesota, 55905, United States
-
Neurocrine Clinical Site
Durham, North Carolina, 27705, United States
-
Neurocrine Clinical Site
Cleveland, Ohio, 44195, United States
-
Neurocrine Clinical Site
Dianalund, 4293, Denmark
-
Neurocrine Clinical Site
Barcelona, 08950, Spain
-
Neurocrine Clinical Site
Madrid, 28034, Spain
-
Neurocrine Clinical Site
Zurich, 8032, Switzerland
-
Neurocrine Clinical Site
London, WC1N 3JH, United Kingdom
Conditions
Explore the condition pages connected to this study.